By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Breaking US News – USA Business MediaBreaking US News – USA Business MediaBreaking US News – USA Business Media
  • Home
  • USA
  • World
  • Business
    • CEO
    • Entrepreneur
    • Founder
    • Journalist
    • Realtor
  • Health
    • Doctor
    • Plastic Surgeon
    • Beauty Cosmetics
  • Sports
    • Athlete
    • Coach
    • Fitness Trainer
  • Cryptocurrency
  • Entertainment
  • Technology
Font ResizerAa
Breaking US News – USA Business MediaBreaking US News – USA Business Media
Font ResizerAa
  • Home
  • USA
  • World
  • Business
  • Health
  • Sports
  • Cryptocurrency
  • Entertainment
  • Technology
Search
  • Home
  • USA
  • World
  • Business
    • CEO
    • Entrepreneur
    • Founder
    • Journalist
    • Realtor
  • Health
    • Doctor
    • Plastic Surgeon
    • Beauty Cosmetics
  • Sports
    • Athlete
    • Coach
    • Fitness Trainer
  • Cryptocurrency
  • Entertainment
  • Technology
Follow US
Home » Blog » Tempus Announces Acquisition of Deep 6 AI
Business

Tempus Announces Acquisition of Deep 6 AI

Jessica Brown
By Jessica Brown
Share
6 Min Read
SHARE

HICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies.

Deep 6 AI enables healthcare organizations to de-risk clinical trials, accelerate recruitment, and generate real-world evidence (RWE) with speed and precision. Its AI-powered software matches patients to clinical trials by mining real-time structured and unstructured electronic medical record (EMR) data across a broad ecosystem, which includes academic medical centers, National Cancer Institute (NCI)-Designated Cancer Centers, and NCI Community Oncology Research Programs.

“Deep 6’s impressive integration infrastructure is well-suited to complement our connectivity efforts, which are central to our ability to support physicians in delivering optimized care for their patients,” said Eric Lefkofsky, Founder and CEO of Tempus. “This acquisition broadens our reach, adding even more providers to our platform, and enhances our ability to deploy critical applications like Next, which helps physicians close care gaps, and TIME, which helps patients find potentially life saving clinical trials.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding Tempus’ acquisition of Deep 6 AI, Deep 6 AI’s customer base, and Tempus’s ability to integrate Deep 6’s operations to enhance its existing products. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; including our ability to realize the expected benefits of the acquisition of Deep 6 AI; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

Share This Article
Facebook Copy Link Print

Fast Four Quiz: Precision Medicine in Cancer

How much do you know about precision medicine in cancer? Test your knowledge with this quick quiz.
Get Started
Rahul Yadav Indian Entrepreneur | India’s Mastermind of IT Innovation

In a time when technology reshapes every aspect of life and business,…

Apple’s ‘Friday Night Baseball’ is back on March 28 with a World Series documentary in tow

Apple's offered Major League Baseball games through the Apple TV app since…

10 Benefits of Forex Hedging Most Traders Don’t Know About

Hedging is possibly the most misunderstood trading method in the world. It's…

Your one-stop resource for medical news and education.

Your one-stop resource for medical news and education.
Sign Up for Free

You Might Also Like

Business

Non-life insurers’ gross direct premium up 6.11% at ₹3.07 lakh cr in FY25

By Olivia Roberts
Business

Talks for proposed India-US trade agreement gaining pace

By Olivia Roberts
Business

LTTS crosses ₹10,000 crore in annual revenue, eyes double-digit growth in FY26, says CEO

By Olivia Roberts
Business

Index Outlook: Nifty 50, Sensex And Nifty Bank To Get Short-Lived Dip Before Rising Back Again

By Olivia Roberts
Breaking US News – USA Business Media
USA
  • USA
  • World
  • Technology
  • Cryptocurrency
Business
  • CEO
  • Founder
  • Journalist
  • Entrepreneur
  • Technology
Health
  • Doctor
  • Beauty Cosmetics
  • Plastic Surgeon
Sports
  • Coach
  • Fitness Trainer
  • Entertainment

© 2017-2025 usabusinessmedia. All Rights Reserved.

Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?